Differential tagging of RNA for preparation of a cell-free DNA/RNA sequencing library
In various aspects, the present disclosure provides methods, compositions, reactions mixtures, kits, and systems for sequencing both RNA and DNA from a single source sample. In some embodiments, RNA is treated so as to differentiate RNA sequences from DNA sequences derived from the same sample. In some embodiments, the RNA and DNA are cell-free polynucleotides.
1. A method of distinguishing sequences of RNA and DNA from a biological sample, the method comprising:
a. obtaining the sample comprising the RNA and the DNA;
b. joining a tag oligonucleotide comprising a tag sequence to the RNA in a reaction comprising an RNA ligase to produce tagged RNA;
c. reverse transcribing the tagged RNA to produce tagged cDNA; and
d. sequencing the DNA and the tagged cDNA;
wherein the joining, reverse transcribing, and sequencing are performed in the presence of the DNA.
2. The method of claim 1 , wherein the RNA and DNA are cell-free nucleic acids.
3. The method of claim 1 , further comprising fragmenting the RNA to produce fragmented RNA prior to joining the tag sequence.
4. The method of claim 3 , wherein the fragmented RNA have an average size within a pre-defined range.
5. The method of claim 2 , wherein (i) the tag oligonucleotide is joined to a 3′ end of the RNA; and (ii) the tag oligonucleotide comprises a primer binding sequence.
6. The method of claim 5 , wherein the reverse transcribing comprises extending a primer hybridized to the primer binding sequence.
7. The method of claim 1 , wherein (i) the reverse transcribing comprises extension of a tagged cDNA along a template switch oligonucleotide (TSO); and (ii) the TSO comprises a universal switch primer sequence.
8. The method of claim 1 , further comprising using a processor to group RNA-derived sequences separately from DNA-derived sequences based on the presence or absence of the tag sequence, or a complement of the tag sequence.
9. The method of claim 8 , further comprising identifying presence or absence of a condition of a subject based on the RNA-derived sequences and the DNA-derived sequences.
10. The method of claim 9 , wherein (i) the condition is cancer; or (ii) the method further comprises treating the subject based on the RNA-derived sequences and the DNA-derived sequences.
11. The method of claim 1 , wherein the tag oligonucleotide is joined to a 3′ end of the RNA.
12. The method of claim 1 , wherein the reverse transcribing comprises extension of the tagged cDNA along a template-switch oligonucleotide (TSO).
13. The method of claim 1 , wherein the sequencing comprises amplifying the tagued cDNA to produce double-stranded tagged cDNA.
14. The method of claim 1 , wherein the sequencing comprises joining sequencing adapters to the tagged cDNA and the DNA.
15. The method of claim 1 , wherein the tag oligonucleotide comprises a unique molecular identifier (UMI), wherein each of a plurality of tagged cDNA molecules is distinguishable from others in the plurality of tagged cDNA molecules based on the UMI.
16. The method of claim 1 , wherein the sample is blood, a blood fraction, plasma, serum, saliva, sputum, urine, semen, transvaginal fluid, cerebrospinal fluid, or stool.
17. The method of claim l, wherein the reverse transcribing comprises extension of primers comprising a random sequence.
18. The method of claim 3 , wherein fragmenting the RNA comprises subjecting the RNA and DNA to conditions that preferentially fragment the RNA.
19. The method of claim 3 , wherein fragmenting the RNA comprises sonication, chemical fragmentation, or heating.
20. The method of claim 3 , wherein the method further comprises dephosphorylating 3′ ends of fragmented RNA.